However, Schanz et al. (2019) did not find a significant difference in AKI incidence between intervention and control groups when using [TIMP-2]·[IGFBP7] to guide AKI management in high risk emergency patients [63]. This evidence concerns the gene TIMP2 and acute kidney injury.